Taiho Oncology, Inc. is the U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., and an indirect subsidiary of Otsuka Holdings Co., Ltd., which contains more than 180 companies, with over 47,000 employees, in 30 countries worldwide. The Otsuka Group of companies, whose origins date back to 1921, aims to contribute to the health of people around the world. Taiho Oncology Inc. is the North American oncology commercial organization for the Otsuka Pharmaceuticals Co., Ltd.

Taiho Oncology Inc.

Taiho Oncology Inc. has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents.

The anti-cancer drug LONSURF (trifluridine and tipiracil) was approved in September 2015 by the FDA, and was introduced in the U.S. market by Taiho Oncology in October 2015.

Established in 2002, in New Jersey, United States, as a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd.

Taiho Pharmaceutical., LTD.

A specialty pharma company, focusing on drug discovery, preclinical research, clinical development, and building a network comprising of production, marketing, research & development in the fields of oncology, allergy and immunology, and urology.

In the company’s primary field of oncology, Taiho Pharmaceutical carries out global development of its mainstay anticancer agents in Japan, the US, Europe, and Asia.

The company also offers consumer health care products including nutritive energy drinks and herbal digestive support drinks.

Established in 1963, in Japan, as a subsidiary of Otsuka Holdings Co., Ltd.

LONSURF - Thymidine-Based Nucleoside Analogue and Thymidine Phosphorylase Inhibitor

Products Details